Archrock (AROC) Tops Q2 EPS by 2c, provides FY23 Guidance

Archrock (NYSE: AROC) reported Q2 EPS of $0.16, $0.02 better than the analyst estimate of $0.14. Revenue for the quarter came in at $247.54 million versus the consensus estimate of $241.77 million.
Guidance:
Raised 2023 Adjusted EBITDA guidance to a range of $430 million to $450 million from $400 million to $430 million. Net Income to a range of 93,800 to $113,800

For earnings history and earnings-related data on Archrock (AROC) click here.

You May Also Be Interested In

• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Calidi Biotherapeutics (CLDI) Reports Q2 Loss of $2.94
• Instil Bio Inc. (TIL) Misses Q2 EPS by 21c